<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-32012" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Palliative Radiation Therapy for Brain Metastases</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Agarwal</surname>
            <given-names>Mohit S.</given-names>
          </name>
          <aff>Medical College of Georgia at Augusta University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Maani</surname>
            <given-names>Elizabeth V.</given-names>
          </name>
          <aff>UT Health San Antonio / South Texas VA</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cascella</surname>
            <given-names>Marco</given-names>
          </name>
          <aff>Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Via Mariano Semmola 80100, Napoli. Italy</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohit Agarwal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Elizabeth Maani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marco Cascella declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-32012.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Up to a third of cancer patients go onto developing brain metastasis, with lung and breast cancer accounting for most cases. The average survival from the time of diagnosis ranges from 2 to 7 months. Our understanding of optimum management has improved with the increasing awareness of the impact of molecular alterations and their prognostic implications. Recently published guidelines have also acknowledged the need to treat specific subsets of cancers separately, a case in point being the American society of clinical oncology guidelines on managing brain metastases due to HER 2 positive breast cancers. However, it is difficult to ignore the central role of radiotherapy in the management of brain metastases. This activity aims to review and evaluate the interprofessional team's role in the provision of radiotherapy to patients with intracranial metastases.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the anatomy and physiology of the blood-brain barrier, which predisposes to the development of intracranial metastasis.</p></list-item><list-item><p>Outline the appropriate indications and contraindications for the use of palliative radiotherapy in patients with Intracranial metastasis.</p></list-item><list-item><p>Describe the equipment, personnel, preparation, and technique involved in providing palliative radiotherapy for intracranial metastasis.</p></list-item><list-item><p>Review the clinical significance and recent advances in the provision of palliative radiotherapy to manage intracranial metastasis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32012&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32012">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-32012.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Central nervous system (CNS) involvement by tumoral metastasis is a potentially life-threatening complication, representing the immediate cause of death in more than 50 percent of the cases.<xref ref-type="bibr" rid="article-32012.r1">[1]</xref><xref ref-type="bibr" rid="article-32012.r2">[2]</xref>&#x000a0;Of note, brain metastasis represents the most common brain tumor in the United States (US).<xref ref-type="bibr" rid="article-32012.r3">[3]</xref>&#x000a0;The most common brain metastasizing tumors include primaries from the lungs, breast, colon, skin (melanoma), and kidney.<xref ref-type="bibr" rid="article-32012.r4">[4]</xref>&#x000a0;Two-year and five-year survival rates of 8.1 percent and 2.4 percent are noted for those with intracranial metastasis across various tumor types.<xref ref-type="bibr" rid="article-32012.r5">[5]</xref>&#x000a0;Moreover, it has been estimated that 10-40 percent of all patients with cancer will eventually develop brain metastasis.<xref ref-type="bibr" rid="article-32012.r6">[6]</xref>&#x000a0;The lack of reporting of the extent of metastatic spread at the time of enrolment into studies and follow-up in advanced cancer patients (who might go onto develop intracranial metastasis later) might be the reason underlying the underdiagnosis of this disease entity.<xref ref-type="bibr" rid="article-32012.r7">[7]</xref></p>
        <p>The most common spread route is through the hematogenous route with the seeding of the brain tissue (microvasculature).<xref ref-type="bibr" rid="article-32012.r8">[8]</xref>&#x000a0;Interactions between the tumor and the microvascular niche, a neuroinflammatory cascade that aids the spread of tumor and neovascularization, have been postulated to underlie the primary tumor's spread.<xref ref-type="bibr" rid="article-32012.r9">[9]</xref>&#x000a0;Intertumoral heterogeneity within the metastatic deposits and a failure to fully understand the clonally selected molecular aberrations might underlie the consistently poor prognosis associated with the tumor's spread to the CNS.<xref ref-type="bibr" rid="article-32012.r10">[10]</xref></p>
        <p>The brain ecosystem represents a unique microenvironment with the inherent ability to aid and limit tumor homing in equal measures. While the microvasculature promotes the spread of tumors, penetration of systemic therapies to the brain tissue is limited.<xref ref-type="bibr" rid="article-32012.r11">[11]</xref>&#x000a0;Understanding the various mechanisms predisposing to the homing of the tumor cells to the brain and basic knowledge of genetic alterations is necessary for planning optimum treatment.</p>
        <p>Radiation therapy aims to mitigate the adverse impact of intracranial metastasis on survival and improve the health-related quality of life (HRQoL).<xref ref-type="bibr" rid="article-32012.r12">[12]</xref>&#x000a0;Recent research in the management of brain metastasis has focused upon using targeted therapies that have good local bioavailability, strategies to provide conformal radiation, limiting adverse effects of irradiation on neurocognitive, and outlining relevant indications for optimum use of immunotherapy.<xref ref-type="bibr" rid="article-32012.r13">[13]</xref><xref ref-type="bibr" rid="article-32012.r14">[14]</xref><xref ref-type="bibr" rid="article-32012.r15">[15]</xref>&#x000a0;Local therapy choice depends upon various parameters, namely patient factors (performance status, stage, and estimated survival), tumor factors (location of metastasis, type of tumor, number, size, and extracranial disease status), and prior treatment history.<xref ref-type="bibr" rid="article-32012.r16">[16]</xref><xref ref-type="bibr" rid="article-32012.r17">[17]</xref></p>
        <p>The first evidence of the utility of whole-brain radiotherapy (WBRT) in palliation of brain metastasis came from Chao et al.<xref ref-type="bibr" rid="article-32012.r18">[18]</xref>&#x000a0;Their paper was also significant for reporting a high incidence of recurrence in irradiated patients.<xref ref-type="bibr" rid="article-32012.r18">[18]</xref>&#x000a0;Subsequent studies by Borgelt et al. were designed to explore the equivalence between different dose fractionation regimens. Both a dose fractionation schedule of 30 Gray in 10 fractions and 37.5 Gray in 15 fractions were equally effective.<xref ref-type="bibr" rid="article-32012.r19">[19]</xref></p>
        <p>This chapter aims to recall, analyze, and select appropriate indications and contraindications for the use of palliative radiotherapy in patients with intracranial metastasis. The clinical significance, technique involved, and recent advances in providing palliative radiotherapy in this clinical setting are also addressed.</p>
      </sec>
      <sec id="article-32012.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>
<bold>Blood Cerebrospinal Fluid Barrier</bold>
</p>
        <p>The choroid plexus epithelial cells connected via tight junctions form the blood-cerebrospinal fluid (CSF) barrier.<xref ref-type="bibr" rid="article-32012.r20">[20]</xref>&#x000a0;Fenestrations and gap junctions within the choroid plexus capillaries enable movement of particles to and fro between the extravascular compartment and CNS.<xref ref-type="bibr" rid="article-32012.r21">[21]</xref>&#x000a0;The C3 complement component's expression by the primary tumor cells has been shown to aid mitogenic stimulus entry within the CNS.<xref ref-type="bibr" rid="article-32012.r22">[22]</xref>&#x000a0;This complement component has been implicated directly in the pathogenesis of leptomeningeal seeding. Activation of the C3a receptor in the choroid plexus epithelium, indeed, has been linked to the disruption of the blood-brain barrier, which allows the entry of amphiregulin and other mitotic signals within the cerebrospinal fluid.<xref ref-type="bibr" rid="article-32012.r22">[22]</xref></p>
        <p>
<bold>Cancer Metastasis</bold>
</p>
        <p>The process of metastasis can be summarized into three steps:<xref ref-type="bibr" rid="article-32012.r23">[23]</xref><xref ref-type="bibr" rid="article-32012.r24">[24]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Intravasation</p>
          </list-item>
          <list-item>
            <p>Extravasation</p>
          </list-item>
          <list-item>
            <p>Adhesive arrest&#x000a0;<xref ref-type="bibr" rid="article-32012.r25">[25]</xref></p>
          </list-item>
        </list>
        <p>Intravasation involves the breakage of tumor cells away from the primary tissue and invasion of the surrounding tissues, venules, capillaries, and lymphatic system. Tumor cells that intravasate into the circulation through the lymphatics or blood vessels interact with macrophages to form actin-rich degradative protrusions&#x02014;these protrusions aid in clearing the extracellular matrix.</p>
        <p>Extravasation involves the egress of these cells from the circulation into the tissue. Circulatory tumors cells, upon metastatic extravasation, undergo adhesive or circulatory arrest. Brain metastases tend to occur at areas with relatively longer mean transit times, such as the white and grey matter interface and watershed territories, which provide cells relatively longer times to egress from the circulation. Tumor cells may lie dormant at the target site of extravasation and arrest, or undergo apoptosis. Cells undergo adhesive circulatory arrest followed by extravasation either as single cells or a tumor embolus.</p>
        <p>Factors that favor increased chances of homing to the brain include a dense microcapillary network and higher blood flow in proportion to other organs. Slowing of tumor cell movement at branch points in capillaries and the larger size of tumor cells compared to red blood cells favor the process of circulatory arrest. Specific interactions between tumor cells and endothelium have been shown to predispose to circulatory arrest. The upregulation of glycosyltransferase ST6GALNAC5 has been shown to lead to the homing of breast cancer tumor cells to the vascular endothelium.</p>
        <p>
<bold>Radiobiology</bold>
</p>
        <p>The selection of dosing of treatment depends upon the biological behavior of the tissue to radiation therapy. Late responding tissues are more susceptible to a single high dose of irradiation than early responding tissues. Most malignant tumors (brain metastasis, glioblastoma multiforme, low-grade glioma) behave as early responding tissues (meningioma, acoustic neuroma), while benign tumors behave as late responding tissues.<xref ref-type="bibr" rid="article-32012.r26">[26]</xref><xref ref-type="bibr" rid="article-32012.r27">[27]</xref></p>
      </sec>
      <sec id="article-32012.s4" sec-type="Indications">
        <title>Indications</title>
        <p>The following factors need to be taken into consideration while deciding upon the treatment options in patients with brain metastasis:<xref ref-type="bibr" rid="article-32012.r16">[16]</xref><xref ref-type="bibr" rid="article-32012.r28">[28]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Volume and number of metastasis</p>
          </list-item>
          <list-item>
            <p>Performance status</p>
          </list-item>
          <list-item>
            <p>Age</p>
          </list-item>
          <list-item>
            <p>Presence of extracranial disease and leptomeningeal disease</p>
          </list-item>
          <list-item>
            <p>Location of metastasis</p>
          </list-item>
          <list-item>
            <p>Site of the resection cavity</p>
          </list-item>
          <list-item>
            <p>Patient's preference</p>
          </list-item>
          <list-item>
            <p>Primary tumor site</p>
          </list-item>
          <list-item>
            <p>Type and molecular profile</p>
          </list-item>
        </list>
        <p>Points favoring the continued use of whole-brain radiotherapy (WBRT) in the setting of intracranial metastasis include:<xref ref-type="bibr" rid="article-32012.r29">[29]</xref><xref ref-type="bibr" rid="article-32012.r30">[30]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Improvement in CNS control</p>
          </list-item>
          <list-item>
            <p>Management of micrometastasis</p>
          </list-item>
          <list-item>
            <p>Reduction in the rate of recurrence</p>
          </list-item>
          <list-item>
            <p>Improvement in overall survival and HRQoL</p>
          </list-item>
          <list-item>
            <p>Prevention of the life-threatening and imminently fatal brain compression syndrome</p>
          </list-item>
        </list>
        <p>Factors favoring the use of hypofractionation dosing include:<xref ref-type="bibr" rid="article-32012.r31">[31]</xref><xref ref-type="bibr" rid="article-32012.r32">[32]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Presence of a large lesion (more than 30 mm)</p>
          </list-item>
          <list-item>
            <p>Proximity to a critical structure</p>
          </list-item>
          <list-item>
            <p>History of previous irradiation</p>
          </list-item>
          <list-item>
            <p>Presence of comorbidities such as stroke and vascular dementia</p>
          </list-item>
        </list>
        <p>
<bold>Whole-Brain Radiotherapy (WBRT)</bold>
</p>
        <p>WBRT is indicated in patients in whom stereotactic radiotherapy or stereotactic radiosurgery (SRS) cannot be performed, including those with leptomeningeal disease, numerous metastasis, low radiation therapy oncology group (RTOG) diagnosis-specific graded prognostic assessment (DS-GPA) scores, or medical contraindications.<xref ref-type="bibr" rid="article-32012.r6">[6]</xref><xref ref-type="bibr" rid="article-32012.r33">[33]</xref></p>
        <p>The presence of comorbidities, location of metastasis, tumor size, patient preference, and the extent of edema determine the choice of treatment in the presence of a single metastasis.<xref ref-type="bibr" rid="article-32012.r34">[34]</xref><xref ref-type="bibr" rid="article-32012.r35">[35]</xref></p>
        <p>Brain metastasis velocity may be used to determine patients who might benefit from WBRT who have distal brain failure after initial SRS.<xref ref-type="bibr" rid="article-32012.r36">[36]</xref>&#x000a0;Brain velocity is defined as the cumulative number of new metastasis developed per year after the receipt of SRS.<xref ref-type="bibr" rid="article-32012.r36">[36]</xref></p>
        <p>The two main concerns that have persisted with the continued preference for the use of WBRT in this setting include:</p>
        <list list-type="bullet">
          <list-item>
            <p>The limited impact on survival outcomes</p>
          </list-item>
          <list-item>
            <p>The potential to lead to neurocognitive decline&#x000a0;<xref ref-type="bibr" rid="article-32012.r29">[29]</xref><xref ref-type="bibr" rid="article-32012.r30">[30]</xref><xref ref-type="bibr" rid="article-32012.r37">[37]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Tumor regression after WBRT has been shown to correlate with improvement in neurocognitive function.<xref ref-type="bibr" rid="article-32012.r30">[30]</xref>&#x000a0;An increase in maximum dose delivered to the hippocampus has been associated with a greater decline in memory, which has provided a degree of credibility to the argument that the maximum dose of radiation that the hippocampus can safely be exposed might be lower than that presumed earlier.<xref ref-type="bibr" rid="article-32012.r38">[38]</xref>&#x000a0;Dose to 100 percent volume (D100) of 9 Gray and maximum dose (Dmax) of 16 Gray, delivered to the hippocampus during the standard fractionation schedule of 30 Gray in 10 fractions have been associated with an impairment in memory.<xref ref-type="bibr" rid="article-32012.r39">[39]</xref><xref ref-type="bibr" rid="article-32012.r40">[40]</xref></p>
        <p>Irradiation to neuro regenerative zone of the hippocampus has been postulated to be associated with neurocognitive deficits.<xref ref-type="bibr" rid="article-32012.r41">[41]</xref>&#x000a0;The hippocampus contains a reserve of neural stem cells (located in the subgranular layer of dentate gyrus), responsible for memory.<xref ref-type="bibr" rid="article-32012.r42">[42]</xref>&#x000a0;Hippocampal granule cells generated from the actively dividing neural stem cells migrate into the granular cell layer.<xref ref-type="bibr" rid="article-32012.r43">[43]</xref>&#x000a0;Neurogenesis within the dentate gyrus has been associated with neurocognition.<xref ref-type="bibr" rid="article-32012.r44">[44]</xref>&#x000a0;The neurogenic stem cell compartment is exquisitely radiosensitive.<xref ref-type="bibr" rid="article-32012.r45">[45]</xref>&#x000a0;Radiation-induced changes in the stromal microenvironment may lead to premature differentiation of neuronal progenitor cells into glial morphology.<xref ref-type="bibr" rid="article-32012.r46">[46]</xref>&#x000a0;Radiotherapy induced cell death has been attributed to an alteration in the NMDA to GABA ratio.<xref ref-type="bibr" rid="article-32012.r47">[47]</xref></p>
        <p>Various tools have been used to assess the neurocognitive dysfunction associated with receipt of radiotherapy to the brain (mainly WBRT). Psychometric tools that have been validated in this setting include Hopkins verbal learning test (HVLT), controlled oral word association, grooved pegboard test, trail making tests a, and b.<xref ref-type="bibr" rid="article-32012.r48">[48]</xref>&#x000a0;A mean 30 percent decline has been noticed on the HVLT with the use of WBRT.<xref ref-type="bibr" rid="article-32012.r49">[49]</xref>&#x000a0;Morris water maze test, which assesses spatial learning and memory (hippocampal function) in preclinical investigations, demonstrates a measurable decline following irradiation.<xref ref-type="bibr" rid="article-32012.r50">[50]</xref>&#x000a0;Impairment in working memory (as conceived in Baddeley model), thought to be independent of hippocampal functioning, has also been reported with cranial irradiation.<xref ref-type="bibr" rid="article-32012.r51">[51]</xref>&#x000a0;This led to the hypothesis that irradiation to other brain regions such as the prefrontal cortex or the striatum may also be responsible for the decline in neurocognitive function associated with cranial irradiation.<xref ref-type="bibr" rid="article-32012.r52">[52]</xref><xref ref-type="bibr" rid="article-32012.r53">[53]</xref>&#x000a0;The use of cholinesterase inhibitors like donepezil has been a study subject in phase three trials in this setting. Benefit has been demonstrated in those with greater pretreatment cognitive deficits.<xref ref-type="bibr" rid="article-32012.r54">[54]</xref>&#x000a0;The use of memantine in addition to HA (hippocampal avoidance)-WBRT has been proposed as a standard of care in those with a good performance status with no metastases in the hippocampal region, who are candidates for WBRT.<xref ref-type="bibr" rid="article-32012.r55">[55]</xref><xref ref-type="bibr" rid="article-32012.r41">[41]</xref></p>
        <p>WBRT with hippocampus avoidance (HA-WBRT), use of SRS, and spatially partitioned adaptive radiotherapy (SPARE) have been used to mitigate the effects of WBRT on the neurocognitive decline. SPARE employs a technique of administering single-fraction SRS over multiple days, limiting the daily treatment time to less than 60 minutes in those with 10-30 brain metastases. This technique has been postulated to have the least possible off-target effects on the hippocampus.<xref ref-type="bibr" rid="article-32012.r56">[56]</xref></p>
        <p>RTOG 933 criteria have described the dosimetric characteristics of dual-arc conventional volumetric modulated arc therapy (DAC-VMAT) in WBRT with hippocampal sparing. Dual arc conventional volumetric modulated arc therapy covers a large field to provide the requisite planned tumor volume.<xref ref-type="bibr" rid="article-32012.r57">[57]</xref></p>
        <p>The following issues may be encountered:</p>
        <list list-type="bullet">
          <list-item>
            <p>Reduction in gantry velocity from one angle to another</p>
          </list-item>
          <list-item>
            <p>Acquisition of limits prescribed for traveling distance for the MLC upon reaching the distal part of the planned target volume<xref ref-type="bibr" rid="article-32012.r57">[57]</xref></p>
          </list-item>
        </list>
        <p>A wide jaw opening has been linked with suboptimal multileaf collimator function (due to interference with movements).<xref ref-type="bibr" rid="article-32012.r57">[57]</xref>&#x000a0;The multi-leaf collimator's failure to shield the organs at risk upon reaching the distal parts of the planned target volume has also been a cause of concern. Measures such as simple split arc technique and split arc partial field (SAPF) technique have been used to prevent suboptimal multileaf collimator movements (limit scatter radiation) and related radiation-induced toxicity to organs at risk. SAPF volumetric modulated arc therapy (VMAT) has been shown to reduce the dose of radiation delivered to the hippocampus and other organs at risk without compromising the planned target volume delivery.<xref ref-type="bibr" rid="article-32012.r57">[57]</xref></p>
        <p>The role of WBRT has been mired in some controversy given the results of the QUARTZ trial, where 538 non-small lung cancer patients with brain metastasis were not eligible for SRS. These patient subgroups were randomized to either WBRT or best supportive care. No significant differences in overall survival, overall HRQoL, or dexamethasone dosing were noticed between the two arms.<xref ref-type="bibr" rid="article-32012.r58">[58]</xref><xref ref-type="bibr" rid="article-32012.r59">[59]</xref></p>
        <p>Though randomized control trials in this setting are lacking, the presence of extensive nodular or symptomatic linear leptomeningeal metastasis is also an indication for WBRT.<xref ref-type="bibr" rid="article-32012.r60">[60]</xref><xref ref-type="bibr" rid="article-32012.r61">[61]</xref></p>
        <p>The Choose Wisely Campaign orchestrated by the American Society for Radiation Oncology has advised against the addition of WBRT in the adjuvant setting to SRS for patients with limited intracranial metastasis.<xref ref-type="bibr" rid="article-32012.r62">[62]</xref></p>
        <p>A continued deferral of WBRT with receipt of multiple SRS courses for progression of recurrent brain metastases (in those who have received initial courses of SRS) has led to higher rates of local control, lower toxicity, and favorable overall and neurological progression-free survival.<xref ref-type="bibr" rid="article-32012.r63">[63]</xref></p>
        <p>
<bold>Stereotactic Radiosurgery&#x000a0;</bold>
</p>
        <p>Emerging randomized data demonstrate a potential beneficial effect on survival from the use of SRS.<xref ref-type="bibr" rid="article-32012.r64">[64]</xref><xref ref-type="bibr" rid="article-32012.r65">[65]</xref>&#x000a0;Stereotactic radiotherapy/SRS is usually indicated in patients with multiple brain metastases with the controlled or uncontrolled extracranial disease along with a Karnofsky performance status of 70 or more.<xref ref-type="bibr" rid="article-32012.r65">[65]</xref>&#x000a0;There have been suggestions that support a combination of surgery followed by SRS in the presence of a single large and multiple small lesions. After surgery, the sequencing of SRS is indicated to improve local control, reduce the incidence of radionecrosis, and leptomeningeal spread.<xref ref-type="bibr" rid="article-32012.r66">[66]</xref><xref ref-type="bibr" rid="article-32012.r67">[67]</xref><xref ref-type="bibr" rid="article-32012.r68">[68]</xref></p>
        <p>SRS provides the advantages of delivering higher dose conformal radiation in a single session, without any inordinate delay in the provision of systemic chemotherapy or immunotherapy.<xref ref-type="bibr" rid="article-32012.r69">[69]</xref>&#x000a0;A very steep gradient dose falls off beyond the prescribed isodose line and adds to the favorable dosimetric characteristics, which lend themselves well to the delivery of dose to intracranial and skull base lesions.<xref ref-type="bibr" rid="article-32012.r70">[70]</xref>&#x000a0;SRS is a standard of care in patients with good performance status and a performance status of more than 70 percent.<xref ref-type="bibr" rid="article-32012.r71">[71]</xref>&#x000a0;SRS has also been more cost-effective than a combination of SRS and WBRT in patients with 1-3 brain metastasis (an oligometastatic disease with a limited metastatic burden), those with an expected median survival of fewer than six months and for those with a less than ten metastasis.<xref ref-type="bibr" rid="article-32012.r72">[72]</xref></p>
        <p>Pre-operative SRS has also been proposed as an adjunct to surgery due to challenges associated with contouring the post-operative surgical cavity, higher local failure rates with the use of WBRT, risks of leptomeningeal spread (with the use of cavity SRS due to sterilization effect), and radiation-induced necrosis (smaller amount of non-malignant brain tissue irradiated, resection of a majority of irradiated tissue). Other potential advantages of pre-operative SRS include increased local control due to improved target delineation, sterilization effect, and improved oxygenation. Lack of pathological confirmation and impaired wound healing are potential disadvantages.<xref ref-type="bibr" rid="article-32012.r73">[73]</xref></p>
        <p>It has been postulated that the decision to use WBRT or SRS should not be solely based upon the number of brain metastases (in those with the number of metastases limited to less than 15). A total cumulative volume of 12-13 cm3 may be considered to a better prognostic indicator of overall survival. More than ten lesions in the brain (have been) can be treated (successfully) using stereotactic radiosurgery.<xref ref-type="bibr" rid="article-32012.r74">[74]</xref><xref ref-type="bibr" rid="article-32012.r75">[75]</xref></p>
        <p>Several studies have demonstrated SRS's utility in brain metastasis due to tumors, traditionally considered to be radioresistant such as melanoma and renal cell carcinoma, with comparable local control rates (compared to non-radioresistant histologies).<xref ref-type="bibr" rid="article-32012.r76">[76]</xref>&#x000a0;SRS has achieved a steep fall off from the target tissues to surrounding normal structures by the use of multiple converging static or moving beams.<xref ref-type="bibr" rid="article-32012.r77">[77]</xref>&#x000a0;This has been able to reduce the risk of damage to the surrounding structures. The dose of radiation is inversely proportional to tumor size. The maximal tolerated doses of radiation derived from the RTOG 9005 study vary from 24 Gy for lesions 20 mm in size, 18 Gy for 21&#x02013;30 mm, and 15 Gy for 31&#x02013;40 mm, respectively.<xref ref-type="bibr" rid="article-32012.r78">[78]</xref></p>
        <p>The risk of radiation necrosis needs to be weighed against the potentially unproven clinical benefit with reirradiation of a local recurrence with SRS, in those who have received SRS earlier.<xref ref-type="bibr" rid="article-32012.r79">[79]</xref></p>
        <p>
<bold>Fractionated Radiosurgery</bold>
</p>
        <p>Fractionated radiosurgery (with 2 -5 fractions) combines the use of steep dose gradients and closer treatment margins associated with SRS, with the radiobiological advantages of fractionation.<xref ref-type="bibr" rid="article-32012.r80">[80]</xref><xref ref-type="bibr" rid="article-32012.r81">[81]</xref>&#x000a0;An improvement in the extent of local control, lower risk of complications, and its position as an alternative option to surgery have been listed as the potential advantages of this procedure. As SRS may fail to treat all microscopic disease and the treatment of choice in the salvage setting is yet to be determined, more studies have been suggested in this setting.</p>
        <p>
<bold>Prophylactic Cranial Irradiation</bold>
</p>
        <p>While prophylactic cranial irradiation is recommended in those with limited-stage small-cell lung cancer (SCLC), who show a good response to systemic therapy, it remains a controversial option for those with extensive-stage SCLC or other unfavorable prognostic factors such as advanced age and presence of multiple comorbidities.<xref ref-type="bibr" rid="article-32012.r82">[82]</xref><xref ref-type="bibr" rid="article-32012.r83">[83]</xref>&#x000a0;Though dosing of 25 Gy in 10 fractions has been advised as the standard, the role of prophylactic intracranial irradiation needs to be re-visited in light of the changes in the treatment landscape brought about by immunotherapy.</p>
      </sec>
      <sec id="article-32012.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Collagen vascular diseases such as lupus, scleroderma, Sjogren syndrome, and inflammatory bowel syndrome are considered absolute contraindications, though it has been argued that these are not absolute contraindications.<xref ref-type="bibr" rid="article-32012.r84">[84]</xref></p>
        <p>Inherited cancer predisposition syndromes such as ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi anemia, Gorlin syndrome, Cockayne syndrome, Down syndrome, Gardner syndrome, Usher syndrome should be carefully addressed.<xref ref-type="bibr" rid="article-32012.r85">[85]</xref><xref ref-type="bibr" rid="article-32012.r86">[86]</xref></p>
      </sec>
      <sec id="article-32012.s6" sec-type="Equipment">
        <title>Equipment</title>
        <p>
<bold>Stereotactic Radiosurgery&#x000a0;</bold>
</p>
        <p>Stereotactic radiation can be delivered by using a linear accelerator, gamma knife unit, and the use of charged particles.<xref ref-type="bibr" rid="article-32012.r87">[87]</xref><xref ref-type="bibr" rid="article-32012.r88">[88]</xref>&#x000a0;The current version of the gamma knife uses 192 Cobalt 60 sources. An inbuilt MRI compatible, stereotactic headframe is used for the immobilization of the head. The headframe adapter has three gantry angles, which are attached to the new positioning system. The positioning system enables movement in the x, y, and z directions, which minimizes the time spent in changing the patient configuration. During SRS, the head frame is secured to the patient's skull bone using titanium pins. The X, Y, and Z coordinates and the gamma angle determine the positioning of the head frame relative to the gamma knife. These coordinates are determined based upon the target coverage required and the treatment planning parameters.</p>
        <p>Treatment planning software uses digital imaging and communication in medicine, and the use of automatic radiation dose balancing algorithms are recent advances introduced with the advent of the gamma knife. The composite dose can be calculated by using a DICOM image and dose file, while the weighing of radiation doses at multiple targets is performed by the automatic dose balancing algorithm blocking of sectors to protect critical structures by the use of dynamic shaping has also been introduced. Prescribed radiation dose and isodose are determined by multiple factors, including target type, target size, and prior radiotherapy or SRS.</p>
      </sec>
      <sec id="article-32012.s7" sec-type="Personnel">
        <title>Personnel</title>
        <p>
<bold>Radiation Therapy Personnel</bold>
</p>
        <p>The WHO document on Quality reassurance in Radiotherapy delineates the following roles for various staff involved in the provision of Radiotherapy<xref ref-type="bibr" rid="article-32012.r89">[89]</xref>.</p>
        <p>Radiation oncologist/ Clinical oncologist (board certified) &#x02013; Responsible solely for the provision of patient care, directly involved in initial planning and treatment, confirmation of delineation of treatment volume, supervision of set up, response assessment as well as management of adverse effects of treatment. Well-versed in cancer care. Must have the capability to delineate the role of radiation in the treatment of specific cancers, while also being aware of the role of other modalities in cancer therapeutics (Surgical and Medical oncology approaches that require the use of Chemotherapy, targeted agents, and immunotherapy drugs). Maintenance of teletherapy and brachytherapy equipment, positioning of the patient including marking and verification, acquiring patient data and planning, review of patient records, and patient safety. Designs the treatment plan. Ensures that limiting dose is delivered to critical organs. Prescription of treatment, monitoring of patients during treatment.</p>
        <p>Medical Radiation Physicist &#x02013; Vital role in monitoring the accuracy of dose of radiation delivered, Role in prevention of dosimetric, geometrical, and treatment planning errors. maintenance and upkeep of metrological equipment (Teletherapy and brachytherapy resources and equipment), acquisition of relevant patient data, delineation of target organs and demarcation of organs at risk, dose calculations and in vivo dosimetry, review of patient records, the performance of quality testing. Also plays an important role in patient safety and personnel safety. Involved in radiation, mechanical and collision avoidance, prevention of electrical hazards, prevention of mechanical failures, upkeep of facilities, shielding from toxic effects of radiation therapy, prevention of contamination, electrical safety measures such as earthing of equipment. Should have basic knowledge of anatomy, physiology, oncology, and radiobiology.</p>
        <p>Medical radiation therapy technicians/ Radiotherapy technologists &#x02013; Knowledge of machine set up, optimum patient positioning on the treatment table, placement of blocks and wedges to achieve the desired positioning. Should have knowledge in Anatomy, physiology, pathology, oncology, radiation physics, radiation biology, treatment planning, radiation protection, radiobiology, and essential aspects of patient care. Performs system quality assurance (constancy) tests.</p>
        <p>Radiation technician &#x02013; usually involved in the preparation of equipment for daily use, insertion of beam modifying equipment, optimum patient positioning, use of aids (wedges and blocks) while positioning, awareness of techniques involved in obtaining Field localization films, measurement of the clinical dose received, maintenance of treatment records and safe usage of radiotherapeutic isotopes.</p>
        <p>Medical dosimetrists &#x02013; Specially educated radiation workforce, provide treatment planning, mould work, calculation of the exact amount to radiation to be delivered.</p>
        <p>Engineers &#x02013; may be responsible for maintenance of equipment, provide technical expertise, functioning of radiation equipment. Usually, receive training from the manufacturer. Expertise in the resolution of technical, mechanical, and electrical faults.</p>
        <p>Personnel in other categories may play an advisory role.</p>
        <p>A historical perspective of the Radiation Oncology workforce and ongoing initiatives to impact recruitment and retention concedes that there has been a stagnation in the number of trained radiation delivery personnel over the years which had led to an acute shortage of Radiation therapists, dosimetrists, and oncology nurses in the United States. They also warn that this shortage is bound to worsen over the coming years<xref ref-type="bibr" rid="article-32012.r90">[90]</xref>.</p>
      </sec>
      <sec id="article-32012.s8" sec-type="Preparation">
        <title>Preparation</title>
        <p>A particular issue with the planning of radiotherapy to the brain is the proximity to functionally significant structures, whose exposure to radiation can lead to significant morbidity. Efficient immobilization and accurate planning are essential to ensure that complications can be minimized.<xref ref-type="bibr" rid="article-32012.r91">[91]</xref><xref ref-type="bibr" rid="article-32012.r92">[92]</xref></p>
      </sec>
      <sec id="article-32012.s9" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>
<bold>Immobilization</bold>
</p>
        <p>The type of material used, method of fixation employed, the percentage area of the material that comes in contact with the patient during the procedure, and technique used to support the patent all affect the procedure's reproducibility. Immobilization may require masks, which may be hazardous for patients with claustrophobia. Pretreatment identification of the patients and setting up limits and appropriate margins, up to which irradiation can be provided in such scenarios, may be useful in achieving optimum results.<xref ref-type="bibr" rid="article-32012.r93">[93]</xref></p>
        <p>
<bold>Compliance of the Patient</bold>
</p>
        <p>The patient's inability to assume a posture for the duration of treatment may compromise the procedure. Anxiety, neurological deficit, and nausea due to raised intracranial tension may lead to movement.<xref ref-type="bibr" rid="article-32012.r94">[94]</xref></p>
        <p>Accuracy of treatment delivered may also vary due to the uncertainty associated with using multiple images acquired through different techniques. Transfer errors associated with each imaging stage might attain significance and affect outcomes.</p>
        <p>
<bold>Reproducibility of the Setup</bold>
</p>
        <p>It depends upon the immobilization technique used. Set up errors in the region of 1.3 to 2 mm have been reported using stereotactic frames. The degree of setup errors encountered during immobilization also depends upon the material of the masks used, ranging from 3 mm with the use of high melting point thermoacrylic systems, 4-5.5 mm using low melting point thermoacrylic systems, and 3.27 mm when thermoplastics are used in combination with a bite block.<xref ref-type="bibr" rid="article-32012.r95">[95]</xref></p>
        <p>
<bold>Internal Organ Movement</bold>
</p>
        <p>The lack of movement of the brain within the cranium limits the effect of internal organ motion, thus, making the use of intrafraction analysis unnecessary.<xref ref-type="bibr" rid="article-32012.r96">[96]</xref></p>
        <p>
<bold>Radiotherapy Fields and Imaging</bold>
</p>
        <p>The timing and frequency of imaging to the brain need to be standardized.<xref ref-type="bibr" rid="article-32012.r97">[97]</xref><xref ref-type="bibr" rid="article-32012.r98">[98]</xref><xref ref-type="bibr" rid="article-32012.r99">[99]</xref>&#x000a0;First day images are accurate to identify gross and systematic data preparation errors. To account for the errors which may be introduced due to other factors, daily images for the first three days are advised. Weekly imaging may be required to account for the variations in the fit of the immobilization device due to the effects of steroid use.&#x000a0;</p>
        <p>A review of the field edges and the isocentre, with the use of images that are representative of all treatment fields, may be required to preserve critical structures in the brain. Double exposures with asymmetrical fields may be required to prevent injury to critical structures when the anatomy of the intracranial structures is not evident in one image.</p>
        <p>Measurement of fiducial surrogates might provide good information when clear images cannot be obtained, either due to the structure of immobilization devices or non-coplanar arrangement of the fields.</p>
        <p>Concomitant exposure to vital structures needs to be reduced while treating benign tumors such as pituitary adenoma. An attempt may be made to target the site of interest while preserving target structures nearby, even at sites for which double exposure may be required.</p>
        <p>Virtual planning CT scanning should be done before irradiation for planning. Virtual CT simulation when part of the brain is being irradiated.</p>
        <p>
<bold>Treatment Planning&#x000a0;</bold>
</p>
        <p>
<bold>Whole-brain Radiotherapy&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The use of parallel fields in WBRT enables coverage of the entire brain. Recent research has focused on reducing the dose of radiation delivered to the parotid gland (an organ at risk) by using WBRT with non-coplanar beams and four field box therapy, which is delivered with the patient's head bent forwards. While bilateral WBRT is delivered using parallel opposed beams, four field box therapy uses anterior, posterior, and bilateral beams. The parallel fields in WBRT include the brain parenchyma, skull, and the spinal cord (until the level of the second cervical vertebrae).<xref ref-type="bibr" rid="article-32012.r100">[100]</xref><xref ref-type="bibr" rid="article-32012.r101">[101]</xref><xref ref-type="bibr" rid="article-32012.r102">[102]</xref><xref ref-type="bibr" rid="article-32012.r103">[103]</xref></p>
          </list-item>
          <list-item>
            <p>3 D planning, which should use CT data fused with T1 weighed gadolinium-enhanced images. Gross tumor volume is defined by the contours of the gadolinium enhancement on T1 weighted image (after adding 2 mm to the contours/borders for adjustments due to MRI fusion uncertainties). The routine use of intensity-modulated treatment should be considered. Dose delivered in a single daily fraction may vary from 16 Gy.</p>
          </list-item>
          <list-item>
            <p>The field of irradiation includes the whole brain with a clearance of 1 cm from the outer table and the base of the skull extending up to the bottom of C2. This might be achieved with the use of lateral parallel opposed fields for virtual simulation.</p>
          </list-item>
          <list-item>
            <p>Fractionation schedules may include 30 Gy in 10 fractions, 20 Gy in 5 fractions, and 12 Gy in 2 fractions, in those with poor performance status.</p>
          </list-item>
        </list>
        <p>
<bold>Stereotactic Radiosurgery</bold>
</p>
        <p>Standard SRS is reserved for lesions less than 3 cm in diameter to reduce the risk of radiation necrosis in the surrounding brain parenchyma. Standard SRS places an isocentre target within individual brain metastases, following which each isocentre is set up and managed sequentially. There has been a move towards anointing a single isocentre within the brain, along with the use of helical tomography and volumetric modulated arc therapy to target multiple metastases at the same time.<xref ref-type="bibr" rid="article-32012.r104">[104]</xref><xref ref-type="bibr" rid="article-32012.r105">[105]</xref></p>
        <p>
<bold>Hypofractionated Stereotactic Radiotherapy</bold>
</p>
        <p>Hypofractionated SRT allows increased time for recovery of surrounding parenchyma by allowing 3-5 fractions on successive or alternate days. The two most common regimens enable the delivery of 25 Gy in 5 fractions and 21 Gy in 3 fractions, respectively.<xref ref-type="bibr" rid="article-32012.r32">[32]</xref></p>
        <p>
<bold>Supratentorial Boost</bold>
</p>
        <p>Supratentorial boost optimization of 2-3 field plan may be achieved by using 3D planning using CT data along with MRI fusion. A boost delivering 10 Gy in 5 fractions may be delivered over the course of one week.<xref ref-type="bibr" rid="article-32012.r106">[106]</xref><xref ref-type="bibr" rid="article-32012.r107">[107]</xref></p>
        <p>
<bold>Posterior Cranial Fossa Boost</bold>
</p>
        <p>Virtual simulation may use opposing lateral fields extending from the posterior fossa to the second cervical vertebrae. Adequate anatomical coverage can be achieved by using MRI fusion, which may aid in the outlining of the contours of the cerebellum and brainstem. A boost delivering 20 Gy in 5 daily fractions may be delivered over one week.<xref ref-type="bibr" rid="article-32012.r108">[108]</xref></p>
        <p>
<bold>Hippocampal Avoidance Region</bold>
</p>
        <p>Bilateral hippocampal contours can be generated on a thin slice MRI-CT fusion image set. The HA region is generated by expanding the hippocampal contour by 5 mm.<xref ref-type="bibr" rid="article-32012.r41">[41]</xref></p>
        <p>
<bold>Contouring of Brain Metastasis</bold>
</p>
        <p>MRI with gadolinium contrast has been advised for treatment planning. Fusion with axial CT is also advised. Gross tumor volume is defined upon gadolinium enhancement with a 1 mm margin. Planning tumor volume or the total treatment volume is calculated by adding a 1-3 mm margin to the gross tumor volume in geometrical form. The tolerance dose for critical structures, while using intensity-modulated radiotherapy treatment, is calculated using the planning at risk volume, which can be created by adding a 3 mm margin to the critical structure.<xref ref-type="bibr" rid="article-32012.r109">[109]</xref></p>
        <p>
<bold>Quality Assurance&#x000a0;</bold>
</p>
        <p>Dose homogeneity (HI) values close to zero indicate superior homogeneity.<xref ref-type="bibr" rid="article-32012.r110">[110]</xref><xref ref-type="bibr" rid="article-32012.r111">[111]</xref></p>
      </sec>
      <sec id="article-32012.s10" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Whole-brain Radiotherapy</bold>
</p>
        <p>Several issues can be associated with the use of WBRT.<xref ref-type="bibr" rid="article-32012.r112">[112]</xref><xref ref-type="bibr" rid="article-32012.r113">[113]</xref><xref ref-type="bibr" rid="article-32012.r114">[114]</xref><xref ref-type="bibr" rid="article-32012.r115">[115]</xref>&#x000a0;Key risks with the use of radiotherapy include the risk of radionecrosis, which might require resection in the future. The increased propensity to cause seizures, especially in people with a history of epilepsy, the possibility of a long duration of steroids, problems likely to be encountered due to the immobilization of the head required for the receipt of treatment, has difficulties patients with claustrophobia.</p>
        <p>Acute adverse effects include skin erythema, alopecia, fatigue, altered sense of taste and smell, and serous otitis media. Memory loss, confusion, and leukoencephalopathy are late adverse effects. A higher burden of brain metastasis, higher integral dose to the calvarium, and use of WBRT are associated with an increased risk of development of leukoencephalopathy in long term survivors.</p>
        <p>The benefits of whole-brain radiotherapy are conditional upon the fact that it may lead to a short term deterioration in the HRQoL, temporary hair loss, and fatigue, the potential for accelerated cognitive loss, and the requirement for multiple hospital visits. The possible risks of bone marrow toxicity, enteritis, and mucositis preclude the use of cerebrospinal radiotherapy in adult solid tumor patients with leptomeningeal metastasis, up to one-fifth of patients who received concomitant intrathecal methotrexate, dexamethasone, and focal radiotherapy presented with grade 3-4 adverse effects.</p>
        <p>
<bold>Stereotactic Radiosurgery</bold>
</p>
        <p>Concerning SRS, local effects must be distinguished by acute and late-onset toxicities.<xref ref-type="bibr" rid="article-32012.r116">[116]</xref><xref ref-type="bibr" rid="article-32012.r117">[117]</xref><xref ref-type="bibr" rid="article-32012.r118">[118]</xref></p>
        <p>
<bold>Local Effects</bold>
</p>
        <p>Pin site trauma, bleeding, and infection due to head frame placement.</p>
        <p>
<bold>Systemic Effects</bold>
</p>
        <p>Acute (within two weeks):</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache, nausea, vomiting, seizures, and worsening neurological deficits, etiologically related to edema, are usually responsive to steroids.</p>
          </list-item>
        </list>
        <p>Late (months to years):</p>
        <list list-type="bullet">
          <list-item>
            <p>Hemorrhage, necrosis, and treatment-related changes (increase in contrast enhancement, necrosis, edema, and mass effect). These may be difficult to distinguish from disease progression and require additional imaging techniques for diagnosis. Modalities used in the treatment of radiation-induced necrosis include steroids, hyperbaric oxygen, anti-vascular endothelial growth factor antibody (bevacizumab), and surgical resection.</p>
          </list-item>
        </list>
        <p>Late effects also include the potential risk of cranial neuropathies, including optic neuropathy, radiation necrosis, and vascular injury. Serious late toxicities of SRS are low.</p>
      </sec>
      <sec id="article-32012.s11" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Prognostication Tools</bold>
</p>
        <p>Recursive partitioning analysis (RPA) developed by Gaspar et al. of the radiation therapy oncology group uses four different parameters: the Karnofsky performance status (KPS), the control of primary tumor, extracerebral disease, and age to classify patients into three different groups. While patients belonging to classes I and II are advised local control with either surgery, radiotherapy, or a combination of the two, those with RPA class III are advised best supportive care only. Disease-specific Gaspar analysis also uses the primary location of the tumor as an additional parameter in prognostication. While Karnofsky performance status and the number of metastasis remain constant across the disease spectrum, other factors differ across diseases. The presence or absence of extracellular matrix has been shown to impact prognosis in disease-specific graded prognostic assessment tools developed for use in gastric and colorectal adenocarcinomas and lung cancer.<xref ref-type="bibr" rid="article-32012.r119">[119]</xref><xref ref-type="bibr" rid="article-32012.r120">[120]</xref><xref ref-type="bibr" rid="article-32012.r7">[7]</xref></p>
        <p>There have been recent attempts to include molecular alterations in the tumor, as can be evidenced by the development of RPA scores for lung cancer using molecular markers such as EGFR mutations or ALK rearrangement, in addition to age, KPS, presence of extracranial metastasis, and the number of brain metastasis. The molecular factors found to have prognostic significance in breast cancer and melanoma include the ER/PR and HER2/neu status and the presence of the BRAFV600E mutation, respectively.</p>
        <p>
<bold>Imaging and Response Assessment</bold>
</p>
        <p>A close assessment of the various criteria used in the assessment of response to treatment in those with CNS metastasis (WHO, RECIST, and Mac Donald criteria) reveals critical gaps in understanding of the definition of disease status and assessment of response to treatment. Issues that are relevant in assessing the extent of disease and response to treatment upon imaging include modality and frequency of assessment, choice of method of assessment (linear, two dimensional and volumetric), differentiation between tumor-related and treatment-related change, the definition of quantum of change that defines treatment response or disease progression, the utility of corticosteroid use, degree of concordance between signs and symptoms and changes on imaging and the impact of systemic disease status on CNS disease progression.<xref ref-type="bibr" rid="article-32012.r121">[121]</xref><xref ref-type="bibr" rid="article-32012.r122">[122]</xref><xref ref-type="bibr" rid="article-32012.r123">[123]</xref><xref ref-type="bibr" rid="article-32012.r124">[124]</xref></p>
        <p>The response assessment in neuro-oncology brain metastases (RANO-BM) committee reported consensus criteria, which defined measurable metastases as contrast-enhancing lesions less than 10 mm in diameter, and are based on the sum of the longest diameter of the target lesions (up to five lesions).&#x000a0;</p>
        <p>
<bold>Response Assessment in Target Lesions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete response: The disappearance of all lesions, which is sustained for at least four weeks, with no appearance of new lesions, without the use of corticosteroids, with stable clinical status or clinical improvement in the patient's condition.</p>
          </list-item>
          <list-item>
            <p>Partial response: 30 percent reduction in the sum of the longest diameter of target lesions from the baseline, which is used as a reference, which is sustained for at least four weeks with no new lesions, with stable corticosteroid use, stable clinical status, or clinical improvement.</p>
          </list-item>
          <list-item>
            <p>Progressive disease: At least a 20 percent increase in the sum of the longest lesion diameter, with the smallest sum on the study taken as reference. A single lesion should increase by a diameter of at least 5 mm to constitute progression.</p>
          </list-item>
        </list>
        <p>
<bold>Response Assessment for Non-target Lesions&#x000a0;</bold>
</p>
        <p>These lesions include metastases with the longest diameter of less than 10 mm, lesions with borders that cannot be measured accurately, dural metastases, bony metastasis in the calvarium, cystic lesions only, and leptomeningeal metastasis has also been defined. These were not based upon measurement of individual lesions, but on qualitative measurements of evidence of disease progression on follow up imaging. Unequivocal progression of non-target lesions may constitute a basis for discontinuation of treatment. Pseudoprogression may be related to treatment response and requires advanced imaging investigations (in addition to routine MRI imaging).</p>
        <p>&#x000a0;Chemical exchange saturation transfer (CEST) imaging is a novel quantitative MRI technique that quantifies compounds, such as amide protons, amine protons, and fast exchanging hydroxyl protons, considered undetectable during structural MRI or even conventional MR spectroscopy. The principle underlying that technique involves the transfer of magnetization from aliphatic protons to labile protons known as the relayed nuclear Overhauser effect (rNOE). Reduced CEST signals and changes in the width NOE tumor peak and amplitude of peak on normal-appearing white matter, which predicted subsequent alterations in tumor volume, have been used to predict SRS response. CEST metrics involving rNOE and amide tumor magnetization ratios have been used to differentiate treatment-associated changes from tumor progression and assess treatment responses in areas such as the brainstem (which are not amenable to biopsy).</p>
        <p>A major challenge to the inclusion of patients in clinical trials is the lack of standardization in measuring the extent of response assessment. According to RANO-BM criteria, patients in whom the metastases' size is less than 10 mm or 5 mm in diameter may be deemed to have an unmeasurable disease. Standardization of techniques involved in MRI acquisition parameters, including optimization of signal to noise ratios and specific contrast to noise ratios is necessary.</p>
        <p>Definitions of survival which have been proposed by the RANO-BM consortium in relation to radiological response assessment in clinical trials include bicompartmental progression-free survival (includes CNS lesions, distant CNS lesions, and non-CNS lesions), CNS progression-free survival, which involves local and distant CNS lesions, non-CNS progression-free survival includes non-CNS lesions only and CNS local progression-free survival which includes CNS lesions only. The inclusion of other parameters that measure the HRQoL, the quantum of corticosteroid use, the progression of clinical neurological symptoms, and neurocognitive function also constitutes important parameters for judging response assessment in clinical trials.</p>
      </sec>
      <sec id="article-32012.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>With the advent of systemic approaches targeting the tumor and advances in radiotherapy techniques, patients' careful selection has assumed greater importance. The use of disease-specific prognostication systems with molecular parameters has put the focus squarely on prognostication. Although it is important to avoid treating those with limited prognosis, it is equally important to provide up to date management to deserving patients. While SRS becomes the standard of care, prevention of neurocognitive decline with HA-WBRT and neuroprotective agents' use holds the promise of improved HRQoL. An interdisciplinary approach that includes a disease management group consultation to provide patient-centered care remains the need of the hour.</p>
        <p>The demarcation between tumor recurrence and radiotherapy related changes remains a subject of further research and demands closer integration of radiologists and nuclear medicine specialists within the multidisciplinary team. Autosegmentation for precise contouring, model-based automated target delineation, automatic generation of treatment plans, and use of omics driven radiation therapy (incorporating omics derived information for treatment planning) are recommended treatment approaches for the future.</p>
      </sec>
      <sec id="article-32012.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32012&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32012">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/32012/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=32012">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-32012.s14">
        <title>References</title>
        <ref id="article-32012.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ou</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>VW</given-names>
              </name>
            </person-group>
            <article-title>CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome.</article-title>
            <source>Lung Cancer</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>130</volume>
            <fpage>201</fpage>
            <page-range>201-207</page-range>
            <pub-id pub-id-type="pmid">30885345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lowery</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Brain metastasis: Unique challenges and open opportunities.</article-title>
            <source>Biochim Biophys Acta Rev Cancer</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>1867</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-57</page-range>
            <pub-id pub-id-type="pmid">27939792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ostrom</surname>
                <given-names>QT</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Barnholtz-Sloan</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Brain metastases: epidemiology.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2018</year>
            <volume>149</volume>
            <fpage>27</fpage>
            <page-range>27-42</page-range>
            <pub-id pub-id-type="pmid">29307358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mampre</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ehresman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alvarado-Estrada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wijesekera</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sarabia-Estrada</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Quinones-Hinojosa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chaichana</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Propensity for different vascular distributions and cerebral edema of intraparenchymal brain metastases from different primary cancers.</article-title>
            <source>J Neurooncol</source>
            <year>2019</year>
            <month>May</month>
            <volume>143</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-122</page-range>
            <pub-id pub-id-type="pmid">30835021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hall</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Djalilian</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Nussbaum</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Long-term survival with metastatic cancer to the brain.</article-title>
            <source>Med Oncol</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>279</fpage>
            <page-range>279-86</page-range>
            <pub-id pub-id-type="pmid">11114706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arvold</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EQ</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Margolin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>NU</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Soffietti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Camidge</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Vogelbaum</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>PY</given-names>
              </name>
            </person-group>
            <article-title>Updates in the management of brain metastases.</article-title>
            <source>Neuro Oncol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>1043</fpage>
            <page-range>1043-65</page-range>
            <pub-id pub-id-type="pmid">27382120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stelzer</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and prognosis of brain metastases.</article-title>
            <source>Surg Neurol Int</source>
            <year>2013</year>
            <volume>4</volume>
            <issue>Suppl 4</issue>
            <fpage>S192</fpage>
            <page-range>S192-202</page-range>
            <pub-id pub-id-type="pmid">23717790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saito</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hatori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Nonaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aoki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iwabuchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ueda</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparison of metastatic brain tumour models using three different methods: the morphological role of the pia mater.</article-title>
            <source>Int J Exp Pathol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>89</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-44</page-range>
            <pub-id pub-id-type="pmid">17999679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berghoff</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Preusser</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The inflammatory microenvironment in brain metastases: potential treatment target?</article-title>
            <source>Chin Clin Oncol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>21</fpage>
            <pub-id pub-id-type="pmid">26112807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lauko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rauf</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ahluwalia</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Medical management of brain metastases.</article-title>
            <source>Neurooncol Adv</source>
            <year>2020</year>
            <season>Jan-Dec</season>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>vdaa015</fpage>
            <pub-id pub-id-type="pmid">32793881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahluwalia</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Winkler</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Targeted and immunotherapeutic approaches in brain metastases.</article-title>
            <source>Am Soc Clin Oncol Educ Book</source>
            <year>2015</year>
            <fpage>67</fpage>
            <page-range>67-74</page-range>
            <pub-id pub-id-type="pmid">25993144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grosu</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Frings</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bentsalo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Oehlke</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bilger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fennell</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Rothe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schneider-Fuchs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Graf</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schmoor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bock</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Egger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Urbach</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lahmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Popp</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG).</article-title>
            <source>BMC Cancer</source>
            <year>2020</year>
            <month>Jun</month>
            <day>08</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>532</fpage>
            <pub-id pub-id-type="pmid">32513138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iorio-Morin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Masson-C&#x000f4;t&#x000e9;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ezahr</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Blanchard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ebacher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mathieu</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Early Gamma Knife stereotactic radiosurgery to the tumor bed of resected brain metastasis for improved local control.</article-title>
            <source>J Neurosurg</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>121 Suppl</volume>
            <fpage>69</fpage>
            <page-range>69-74</page-range>
            <pub-id pub-id-type="pmid">25434939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gondi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pugh</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Tome</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Caine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Corn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kanner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rowley</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kundapur</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>DeNittis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Greenspoon</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Konski</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Bauman</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wendland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kachnic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Dec</month>
            <day>01</day>
            <volume>32</volume>
            <issue>34</issue>
            <fpage>3810</fpage>
            <page-range>3810-6</page-range>
            <pub-id pub-id-type="pmid">25349290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Giacomo</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cerase</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lofiego</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Piazzini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Calabr&#x000f2;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gambale</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Covre</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maio</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Immunotherapy of brain metastases: breaking a "dogma".</article-title>
            <source>J Exp Clin Cancer Res</source>
            <year>2019</year>
            <month>Oct</month>
            <day>17</day>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>419</fpage>
            <pub-id pub-id-type="pmid">31623643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buecker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>XM</given-names>
              </name>
              <name>
                <surname>Jaenke</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Risk factors to identify patients who may not benefit from whole brain irradiation for brain metastases - a single institution analysis.</article-title>
            <source>Radiat Oncol</source>
            <year>2019</year>
            <month>Mar</month>
            <day>11</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <pub-id pub-id-type="pmid">30866972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sch&#x000fc;ttrumpf</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Niyazi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nachbichler</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Manapov</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Siefert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Belka</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors for survival and radiation necrosis after stereotactic radiosurgery alone or in combination with whole brain radiation therapy for 1-3 cerebral metastases.</article-title>
            <source>Radiat Oncol</source>
            <year>2014</year>
            <month>May</month>
            <day>02</day>
            <volume>9</volume>
            <fpage>105</fpage>
            <pub-id pub-id-type="pmid">24885624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>CHAO</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>PHILLIPS</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>NICKSON</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Roentgen-ray therapy of cerebral metastases.</article-title>
            <source>Cancer</source>
            <year>1954</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>682</fpage>
            <page-range>682-9</page-range>
            <pub-id pub-id-type="pmid">13172684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borgelt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gelber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hendrickson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>1981</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>12</issue>
            <fpage>1633</fpage>
            <page-range>1633-8</page-range>
            <pub-id pub-id-type="pmid">6174490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liddelow</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Development of the choroid plexus and blood-CSF barrier.</article-title>
            <source>Front Neurosci</source>
            <year>2015</year>
            <volume>9</volume>
            <fpage>32</fpage>
            <pub-id pub-id-type="pmid">25784848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milhorat</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Structure and function of the choroid plexus and other sites of cerebrospinal fluid formation.</article-title>
            <source>Int Rev Cytol</source>
            <year>1976</year>
            <volume>47</volume>
            <fpage>225</fpage>
            <page-range>225-88</page-range>
            <pub-id pub-id-type="pmid">136427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boire</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shieh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Macalinao</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Pentsova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Massagu&#x000e9;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis.</article-title>
            <source>Cell</source>
            <year>2017</year>
            <month>Mar</month>
            <day>09</day>
            <volume>168</volume>
            <issue>6</issue>
            <fpage>1101</fpage>
            <page-range>1101-1113.e13</page-range>
            <pub-id pub-id-type="pmid">28283064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seyfried</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Huysentruyt</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>On the origin of cancer metastasis.</article-title>
            <source>Crit Rev Oncog</source>
            <year>2013</year>
            <volume>18</volume>
            <issue>1-2</issue>
            <fpage>43</fpage>
            <page-range>43-73</page-range>
            <pub-id pub-id-type="pmid">23237552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bos</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Nadal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gomis</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>DX</given-names>
              </name>
              <name>
                <surname>Minn</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>van de Vijver</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gerald</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Foekens</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Massagu&#x000e9;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Genes that mediate breast cancer metastasis to the brain.</article-title>
            <source>Nature</source>
            <year>2009</year>
            <month>Jun</month>
            <day>18</day>
            <volume>459</volume>
            <issue>7249</issue>
            <fpage>1005</fpage>
            <page-range>1005-9</page-range>
            <pub-id pub-id-type="pmid">19421193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fares</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fares</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Khachfe</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Salhab</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Fares</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Molecular principles of metastasis: a hallmark of cancer revisited.</article-title>
            <source>Signal Transduct Target Ther</source>
            <year>2020</year>
            <month>Mar</month>
            <day>12</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <pub-id pub-id-type="pmid">32296047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Linskey</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Stereotactic radiosurgery versus stereotactic radiotherapy for patients with vestibular schwannoma: a Leksell Gamma Knife Society 2000 debate.</article-title>
            <source>J Neurosurg</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>93 Suppl 3</volume>
            <fpage>90</fpage>
            <page-range>90-5</page-range>
            <pub-id pub-id-type="pmid">11143270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santacroce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kamp</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Budach</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>H&#x000e4;nggi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Radiobiology of radiosurgery for the central nervous system.</article-title>
            <source>Biomed Res Int</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>362761</fpage>
            <pub-id pub-id-type="pmid">24490157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernhardt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Adeberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bozorgmehr</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Opfermann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hoerner-Rieber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kappes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herth</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Heu&#x000df;el</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Warth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Debus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rieken</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy.</article-title>
            <source>J Neurooncol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>134</volume>
            <issue>1</issue>
            <fpage>205</fpage>
            <page-range>205-212</page-range>
            <pub-id pub-id-type="pmid">28560661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsao</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rakovitch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Laperriere</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sahgal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2012</year>
            <month>Apr</month>
            <day>18</day>
            <volume>2012</volume>
            <issue>4</issue>
            <fpage>CD003869</fpage>
            <pub-id pub-id-type="pmid">22513917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaspar</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Prabhu</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Hdeib</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McCracken</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lasker</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>McDermott</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Kalkanis</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Whole Brain Radiation Therapy in Adults With Newly Diagnosed Metastatic Brain Tumors.</article-title>
            <source>Neurosurgery</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>E159</fpage>
            <page-range>E159-E162</page-range>
            <pub-id pub-id-type="pmid">30629211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eaton</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Gebhardt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Prabhu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Crocker</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Hypofractionated radiosurgery for intact or resected brain metastases: defining the optimal dose and fractionation.</article-title>
            <source>Radiat Oncol</source>
            <year>2013</year>
            <month>Jun</month>
            <day>07</day>
            <volume>8</volume>
            <fpage>135</fpage>
            <pub-id pub-id-type="pmid">23759065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masucci</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Hypofractionated Radiation Therapy for Large Brain Metastases.</article-title>
            <source>Front Oncol</source>
            <year>2018</year>
            <volume>8</volume>
            <fpage>379</fpage>
            <pub-id pub-id-type="pmid">30333955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kazda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Posp&#x000ed;&#x00161;il</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dole&#x0017e;elov&#x000e1;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jan&#x0010d;&#x000e1;lek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Slampa</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Whole brain radiotherapy: Consequences for personalized medicine.</article-title>
            <source>Rep Pract Oncol Radiother</source>
            <year>2013</year>
            <month>Apr</month>
            <day>19</day>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>133</fpage>
            <page-range>133-8</page-range>
            <pub-id pub-id-type="pmid">24416544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soffietti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rud&#x00101;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mutani</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Management of brain metastases.</article-title>
            <source>J Neurol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>249</volume>
            <issue>10</issue>
            <fpage>1357</fpage>
            <page-range>1357-69</page-range>
            <pub-id pub-id-type="pmid">12382150</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elaimy</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Mackay</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Lamoreaux</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Fairbanks</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Demakas</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Cooke</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Peressini</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Holbrook</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients.</article-title>
            <source>World J Surg Oncol</source>
            <year>2011</year>
            <month>Jul</month>
            <day>05</day>
            <volume>9</volume>
            <fpage>69</fpage>
            <pub-id pub-id-type="pmid">21729314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McTyre</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Cramer</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Ayala-Peacock</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Bourland</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Watabe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Laxton</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Tatter</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Brain Metastasis Velocity: A Novel Prognostic Metric Predictive of Overall Survival and Freedom From Whole-Brain Radiation Therapy After Distant Brain Failure Following Upfront Radiosurgery Alone.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>98</volume>
            <issue>1</issue>
            <fpage>131</fpage>
            <page-range>131-141</page-range>
            <pub-id pub-id-type="pmid">28586952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kotecha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gondi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ahluwalia</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Brastianos</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in managing brain metastasis.</article-title>
            <source>F1000Res</source>
            <year>2018</year>
            <volume>7</volume>
            <pub-id pub-id-type="pmid">30473769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okoukoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McTyre</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Ayala Peacock</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Peiffer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Strowd</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cramer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hinson</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Rapp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Metheny-Barlow</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Hippocampal dose volume histogram predicts Hopkins Verbal Learning Test scores after brain irradiation.</article-title>
            <source>Adv Radiat Oncol</source>
            <year>2017</year>
            <season>Oct-Dec</season>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>624</fpage>
            <page-range>624-629</page-range>
            <pub-id pub-id-type="pmid">29204530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gondi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tom&#x000e9;</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Why avoid the hippocampus? A comprehensive review.</article-title>
            <source>Radiother Oncol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>370</fpage>
            <page-range>370-6</page-range>
            <pub-id pub-id-type="pmid">20970214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsai</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy: a prospective study.</article-title>
            <source>Radiat Oncol</source>
            <year>2015</year>
            <month>Dec</month>
            <day>10</day>
            <volume>10</volume>
            <fpage>253</fpage>
            <pub-id pub-id-type="pmid">26654128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Gondi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pugh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tome</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Wefel</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Bovi</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Konski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khuntia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Grosshans</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Benzinger</surname>
                <given-names>TLS</given-names>
              </name>
              <name>
                <surname>Bruner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Roberge</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kundapur</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Devisetty</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Usuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Stea</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laack</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Kruser</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Chmura</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Deshmukh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Kachnic</surname>
                <given-names>LA</given-names>
              </name>
              <collab>for NRG Oncology</collab>
            </person-group>
            <article-title>Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.</article-title>
            <source>J Clin Oncol</source>
            <year>2020</year>
            <month>Apr</month>
            <day>01</day>
            <volume>38</volume>
            <issue>10</issue>
            <fpage>1019</fpage>
            <page-range>1019-1029</page-range>
            <pub-id pub-id-type="pmid">32058845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rolando</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Neural stem cell of the hippocampus: development, physiology regulation, and dysfunction in disease.</article-title>
            <source>Curr Top Dev Biol</source>
            <year>2014</year>
            <volume>107</volume>
            <fpage>183</fpage>
            <page-range>183-206</page-range>
            <pub-id pub-id-type="pmid">24439807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Imayoshi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tamamaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tatebayashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hitoshi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neural stem cells and neuro/gliogenesis in the central nervous system: understanding the structural and functional plasticity of the developing, mature, and diseased brain.</article-title>
            <source>J Physiol Sci</source>
            <year>2016</year>
            <month>May</month>
            <volume>66</volume>
            <issue>3</issue>
            <fpage>197</fpage>
            <page-range>197-206</page-range>
            <pub-id pub-id-type="pmid">26578509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piatti</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Ewell</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Leutgeb</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Neurogenesis in the dentate gyrus: carrying the message or dictating the tone.</article-title>
            <source>Front Neurosci</source>
            <year>2013</year>
            <volume>7</volume>
            <fpage>50</fpage>
            <pub-id pub-id-type="pmid">23576950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bender</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Tom&#x000e9;</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>On the estimation of the location of the hippocampus in the context of hippocampal avoidance whole brain radiotherapy treatment planning.</article-title>
            <source>Technol Cancer Res Treat</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>425</fpage>
            <page-range>425-32</page-range>
            <pub-id pub-id-type="pmid">19925026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nieder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Andratschke</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Astner</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Experimental concepts for toxicity prevention and tissue restoration after central nervous system irradiation.</article-title>
            <source>Radiat Oncol</source>
            <year>2007</year>
            <month>Jun</month>
            <day>30</day>
            <volume>2</volume>
            <fpage>23</fpage>
            <pub-id pub-id-type="pmid">17603905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Coultrap</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pinnix</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Tailor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ang</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Browning</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Grosshans</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Radiation induces acute alterations in neuronal function.</article-title>
            <source>PLoS One</source>
            <year>2012</year>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>e37677</fpage>
            <pub-id pub-id-type="pmid">22662188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Day</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zienius</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gehring</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grosshans</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Taphoorn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Dec</month>
            <day>18</day>
            <volume>2014</volume>
            <issue>12</issue>
            <fpage>CD011335</fpage>
            <pub-id pub-id-type="pmid">25519950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Pugh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Laack</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Wefel</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Khuntia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Choucair</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Roberge</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kavadi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bentzen</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Watkins-Bruner</surname>
                <given-names>D</given-names>
              </name>
              <collab>Radiation Therapy Oncology Group (RTOG)</collab>
            </person-group>
            <article-title>Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.</article-title>
            <source>Neuro Oncol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>1429</fpage>
            <page-range>1429-37</page-range>
            <pub-id pub-id-type="pmid">23956241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belarbi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jopson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arellano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fike</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rosi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>CCR2 deficiency prevents neuronal dysfunction and cognitive impairments induced by cranial irradiation.</article-title>
            <source>Cancer Res</source>
            <year>2013</year>
            <month>Feb</month>
            <day>01</day>
            <volume>73</volume>
            <issue>3</issue>
            <fpage>1201</fpage>
            <page-range>1201-10</page-range>
            <pub-id pub-id-type="pmid">23243025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gondi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Tom&#x000e9;</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2012</year>
            <month>Jul</month>
            <day>15</day>
            <volume>83</volume>
            <issue>4</issue>
            <fpage>e487</fpage>
            <page-range>e487-93</page-range>
            <pub-id pub-id-type="pmid">22209148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Duman</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Dougherty</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Grosshans</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Cranial irradiation induces axon initial segment dysfunction and neuronal injury in the prefrontal cortex and impairs hippocampal coupling.</article-title>
            <source>Neurooncol Adv</source>
            <year>2020</year>
            <season>Jan-Dec</season>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>vdaa058</fpage>
            <pub-id pub-id-type="pmid">32642710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Acharya</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Najafi</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Syage</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Minasyan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Kawashita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Giedzinski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Parihar</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Baulch</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Limoli</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Elimination of microglia improves cognitive function following cranial irradiation.</article-title>
            <source>Sci Rep</source>
            <year>2016</year>
            <month>Aug</month>
            <day>12</day>
            <volume>6</volume>
            <fpage>31545</fpage>
            <pub-id pub-id-type="pmid">27516055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapp</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Case</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Peiffer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Naughton</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Stieber</surname>
                <given-names>VW</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Falchuk</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Piephoff</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Edenfield</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Giguere</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Loghin</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>EG</given-names>
              </name>
            </person-group>
            <article-title>Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2015</year>
            <month>May</month>
            <day>20</day>
            <volume>33</volume>
            <issue>15</issue>
            <fpage>1653</fpage>
            <page-range>1653-9</page-range>
            <pub-id pub-id-type="pmid">25897156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lynch</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Preservation of cognitive function following whole brain radiotherapy in patients with brain metastases: Complications, treatments, and the emerging role of memantine.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>657</fpage>
            <page-range>657-662</page-range>
            <pub-id pub-id-type="pmid">30200844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Sahgal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Detsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Myrehaug</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Husain</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Carty</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sarfehnia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chugh</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ruschin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Single-Fraction Stereotactic Radiosurgery Versus Hippocampal-Avoidance Whole Brain Radiation Therapy for Patients With 10 to 30 Brain Metastases: A Dosimetric Analysis.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2019</year>
            <month>Oct</month>
            <day>01</day>
            <volume>105</volume>
            <issue>2</issue>
            <fpage>394</fpage>
            <page-range>394-399</page-range>
            <pub-id pub-id-type="pmid">31283978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuen</surname>
                <given-names>AHL</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>AKL</given-names>
              </name>
              <name>
                <surname>Mak</surname>
                <given-names>PCY</given-names>
              </name>
            </person-group>
            <article-title>Volumetric modulated arc therapy (VMAT) for hippocampal-avoidance whole brain radiation therapy: planning comparison with Dual-arc and Split-arc partial-field techniques.</article-title>
            <source>Radiat Oncol</source>
            <year>2020</year>
            <month>Feb</month>
            <day>18</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <pub-id pub-id-type="pmid">32070385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Chakraborty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Laskar</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Mummudi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Upasani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prabhash</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Noronha</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Purandare</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Badhe</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Applying the QUARTZ Trial Results in Clinical Practice: Development of a Prognostic Model Predicting Poor Outcomes for Non-small Cell Lung Cancers with Brain Metastases.</article-title>
            <source>Clin Oncol (R Coll Radiol)</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>382</fpage>
            <page-range>382-390</page-range>
            <pub-id pub-id-type="pmid">29499878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulvenna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nankivell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Faivre-Finn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McColl</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brisbane</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ardron</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Waite</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bayman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pugh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sydes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Parmar</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Langley</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Oct</month>
            <day>22</day>
            <volume>388</volume>
            <issue>10055</issue>
            <fpage>2004</fpage>
            <page-range>2004-2014</page-range>
            <pub-id pub-id-type="pmid">27604504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study.</article-title>
            <source>Radiat Oncol</source>
            <year>2020</year>
            <month>Jul</month>
            <day>31</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>185</fpage>
            <pub-id pub-id-type="pmid">32736566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mack</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Baumert</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;fer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hattingen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Scheffler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Herrlinger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Glas</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Therapy of leptomeningeal metastasis in solid tumors.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>43</volume>
            <fpage>83</fpage>
            <page-range>83-91</page-range>
            <pub-id pub-id-type="pmid">26827696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niska</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Keole</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Pockaj</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Halyard</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Northfelt</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Wasif</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Choosing wisely after publication of level I evidence in breast cancer radiotherapy.</article-title>
            <source>Breast Cancer (Dove Med Press)</source>
            <year>2018</year>
            <volume>10</volume>
            <fpage>31</fpage>
            <page-range>31-37</page-range>
            <pub-id pub-id-type="pmid">29445299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bretzinger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fennell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nieder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lorenz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oehlke</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Grosu</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Specht</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Combs</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection.</article-title>
            <source>Cancer Med</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>2350</fpage>
            <page-range>2350-2359</page-range>
            <pub-id pub-id-type="pmid">29745035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graber</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Cobbs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Use of Stereotactic Radiosurgery in the Treatment of Adults With Metastatic Brain Tumors.</article-title>
            <source>Neurosurgery</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>E168</fpage>
            <page-range>E168-E170</page-range>
            <pub-id pub-id-type="pmid">30629225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soliman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sahgal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases.</article-title>
            <source>Oncotarget</source>
            <year>2016</year>
            <month>Mar</month>
            <day>15</day>
            <volume>7</volume>
            <issue>11</issue>
            <fpage>12318</fpage>
            <page-range>12318-30</page-range>
            <pub-id pub-id-type="pmid">26848525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gans</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Raper</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bregy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heros</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lally</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Morcos</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Heros</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Komotar</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>The role of radiosurgery to the tumor bed after resection of brain metastases.</article-title>
            <source>Neurosurgery</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>72</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-25; discussion 325-6</page-range>
            <pub-id pub-id-type="pmid">23208065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Natarajan</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Rushing</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jutzy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Choudhury</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Moravan</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Fecci</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Adamson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chmura</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Kirkpatrick</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Salama</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Predicting intracranial progression following stereotactic radiosurgery for brain metastases: Implications for post SRS imaging.</article-title>
            <source>J Radiosurg SBRT</source>
            <year>2019</year>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>179</fpage>
            <page-range>179-187</page-range>
            <pub-id pub-id-type="pmid">31998538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathieu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kondziolka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Flickinger</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fortin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kenny</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mongia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niranjan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lunsford</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Tumor bed radiosurgery after resection of cerebral metastases.</article-title>
            <source>Neurosurgery</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>817</fpage>
            <page-range>817-23; discussion 823-4</page-range>
            <pub-id pub-id-type="pmid">18414136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lehrer</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Vallow</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ruiz-Garcia</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zaorsky</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Trifiletti</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases.</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>Oct</month>
            <day>07</day>
            <volume>19</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">30301252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Selch</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>De Salles</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Accelerator-based stereotactic radiosurgery for brainstem metastases.</article-title>
            <source>Neurosurgery</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>953</fpage>
            <page-range>953-8; discussion 958</page-range>
            <pub-id pub-id-type="pmid">21997541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilbo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Knisely</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Stereotactic radiosurgery of the brain: a review of common indications.</article-title>
            <source>Chin Clin Oncol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>Suppl 2</issue>
            <fpage>S14</fpage>
            <pub-id pub-id-type="pmid">28917252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazzola</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Corradini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gregucci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Figlia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fiorentino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alongi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases.</article-title>
            <source>Front Oncol</source>
            <year>2019</year>
            <volume>9</volume>
            <fpage>206</fpage>
            <pub-id pub-id-type="pmid">31019891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Routman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chaichana</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Laack</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Parney</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Trifiletti</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Preoperative Stereotactic Radiosurgery for Brain Metastases.</article-title>
            <source>Front Neurol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>959</fpage>
            <pub-id pub-id-type="pmid">30542316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sayan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zoto Mustafayev</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sahin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kefelioglu</surname>
                <given-names>ESS</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kurup</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Balmuk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gungor</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ohri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ozyar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Atalar</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of response to stereotactic radiosurgery in patients with radioresistant brain metastases.</article-title>
            <source>Radiat Oncol J</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>265</fpage>
            <page-range>265-270</page-range>
            <pub-id pub-id-type="pmid">31918464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amsbaugh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Dragun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dunlap</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Boling</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Dose-Volume Response Relationship for Brain Metastases Treated with Frameless Single-Fraction Linear Accelerator-Based Stereotactic Radiosurgery.</article-title>
            <source>Cureus</source>
            <year>2016</year>
            <month>Apr</month>
            <day>27</day>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>e587</fpage>
            <pub-id pub-id-type="pmid">27284495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanson</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Elaimy</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Lamoreaux</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Demakas</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Fairbanks</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Mackay</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cooke</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Thumma</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>A concise review of the efficacy of stereotactic radiosurgery in the management of melanoma and renal cell carcinoma brain metastases.</article-title>
            <source>World J Surg Oncol</source>
            <year>2012</year>
            <month>Aug</month>
            <day>29</day>
            <volume>10</volume>
            <fpage>176</fpage>
            <pub-id pub-id-type="pmid">22931379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sahgal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruschin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Verbakel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Stereotactic radiosurgery alone for multiple brain metastases? A review of clinical and technical issues.</article-title>
            <source>Neuro Oncol</source>
            <year>2017</year>
            <month>Apr</month>
            <day>01</day>
            <volume>19</volume>
            <issue>suppl_2</issue>
            <fpage>ii2</fpage>
            <page-range>ii2-ii15</page-range>
            <pub-id pub-id-type="pmid">28380635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaw</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Souhami</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dinapoli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kline</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Loeffler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Farnan</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2000</year>
            <month>May</month>
            <day>01</day>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>291</fpage>
            <page-range>291-8</page-range>
            <pub-id pub-id-type="pmid">10802351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nieder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yobuta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Manns&#x000e5;ker</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Second Re-irradiation of Brain Metastases: A Review of Studies Involving Stereotactic Radiosurgery.</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>Dec</month>
            <day>11</day>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>e3712</fpage>
            <pub-id pub-id-type="pmid">30788201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scora</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>PF</given-names>
              </name>
            </person-group>
            <article-title>Fractionated (split dose) radiosurgery in patients with recurrent brain metastases: implications for survival.</article-title>
            <source>Br J Neurosurg</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>491</fpage>
            <page-range>491-5</page-range>
            <pub-id pub-id-type="pmid">17852114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elhateer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Muanza</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Roberge</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ruo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eldebawy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patrocinio</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shenouda</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Souhami</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Fractionated stereotactic radiotherapy in the treatment of pituitary macroadenomas.</article-title>
            <source>Curr Oncol</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>286</fpage>
            <page-range>286-92</page-range>
            <pub-id pub-id-type="pmid">19079630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aup&#x000e9;rin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arriagada</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pignon</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Le P&#x000e9;choux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gregor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kristjansen</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Ueoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aisner</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.</article-title>
            <source>N Engl J Med</source>
            <year>1999</year>
            <month>Aug</month>
            <day>12</day>
            <volume>341</volume>
            <issue>7</issue>
            <fpage>476</fpage>
            <page-range>476-84</page-range>
            <pub-id pub-id-type="pmid">10441603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farris</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Wheless</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Soike</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Masters</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Helis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Cramer</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lycan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Petty</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Leyrer</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Blackstock</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Limited-Stage Small Cell Lung Cancer: Is Prophylactic Cranial Irradiation Necessary?</article-title>
            <source>Pract Radiat Oncol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>e599</fpage>
            <page-range>e599-e607</page-range>
            <pub-id pub-id-type="pmid">31271904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lehrer</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trifiletti</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Zaorsky</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Toxicity after radiotherapy in patients with historically accepted contraindications to treatment (CONTRAD): An international systematic review and meta-analysis.</article-title>
            <source>Radiother Oncol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>135</volume>
            <fpage>147</fpage>
            <page-range>147-152</page-range>
            <pub-id pub-id-type="pmid">31015161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pollard</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gatti</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Clinical radiation sensitivity with DNA repair disorders: an overview.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2009</year>
            <month>Aug</month>
            <day>01</day>
            <volume>74</volume>
            <issue>5</issue>
            <fpage>1323</fpage>
            <page-range>1323-31</page-range>
            <pub-id pub-id-type="pmid">19616740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergom</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Higginson</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Abazeed</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Arun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bentzen</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Kerns</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Keen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Litton</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Reiner</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Riaz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rosenstein</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Sawakuchi</surname>
                <given-names>GO</given-names>
              </name>
              <name>
                <surname>Shaitelman</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2019</year>
            <month>Nov</month>
            <day>15</day>
            <volume>105</volume>
            <issue>4</issue>
            <fpage>698</fpage>
            <page-range>698-712</page-range>
            <pub-id pub-id-type="pmid">31381960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Girvigian</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Stereotactic radiosurgery: instrumentation and theoretical aspects-part 1.</article-title>
            <source>Perm J</source>
            <year>2005</year>
            <season>Fall</season>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>23</fpage>
            <page-range>23-6</page-range>
            <pub-id pub-id-type="pmid">22811641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsao</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Rakovitch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Laperriere</surname>
                <given-names>N</given-names>
              </name>
              <collab>Supportive Care Guidelines Group of Cancer Care Ontario's Program in Evidence-based Care</collab>
            </person-group>
            <article-title>Radiotherapeutic management of brain metastases: a systematic review and meta-analysis.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>256</fpage>
            <page-range>256-73</page-range>
            <pub-id pub-id-type="pmid">15951117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bush</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Quality assurance in radiation therapy: clinical and physical aspects. Future plans: clinical.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>1984</year>
            <month>Jun</month>
            <volume>10 Suppl 1</volume>
            <fpage>39</fpage>
            <page-range>39-41</page-range>
            <pub-id pub-id-type="pmid">6735794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kresl</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Drummond</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>A historical perspective of the radiation oncology workforce and ongoing initiatives to impact recruitment and retention.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2004</year>
            <month>Sep</month>
            <day>01</day>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-14</page-range>
            <pub-id pub-id-type="pmid">15337534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oermann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Erickson</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hanscom</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HU</given-names>
              </name>
              <name>
                <surname>Eldabh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kalhorn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McGrail</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Subramaniam</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jean</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>CyberKnife enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures.</article-title>
            <source>J Hematol Oncol</source>
            <year>2010</year>
            <month>Jun</month>
            <day>09</day>
            <volume>3</volume>
            <fpage>22</fpage>
            <pub-id pub-id-type="pmid">20534128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Purdy</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Dose to normal tissues outside the radiation therapy patient's treated volume: a review of different radiation therapy techniques.</article-title>
            <source>Health Phys</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>95</volume>
            <issue>5</issue>
            <fpage>666</fpage>
            <page-range>666-76</page-range>
            <pub-id pub-id-type="pmid">18849701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leech</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coffey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mast</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moura</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Osztavics</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pasini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vaandering</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>ESTRO ACROP guidelines for positioning, immobilisation and position verification of head and neck patients for radiation therapists.</article-title>
            <source>Tech Innov Patient Support Radiat Oncol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>1</volume>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">32095536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tominaga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Araki</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shimohigashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ishihara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kanetake</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sakata</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Iwashita</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Accuracy of positioning and irradiation targeting for multiple targets in intracranial image-guided radiation therapy: a phantom study.</article-title>
            <source>Phys Med Biol</source>
            <year>2014</year>
            <month>Dec</month>
            <day>21</day>
            <volume>59</volume>
            <issue>24</issue>
            <fpage>7753</fpage>
            <page-range>7753-66</page-range>
            <pub-id pub-id-type="pmid">25419723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Upasani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Master</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Phurailatpam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nojin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kannan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Godasastri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jalali</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Assessment of three-dimensional set-up errors using megavoltage computed tomography (MVCT) during image-guided intensity-modulated radiation therapy (IMRT) for craniospinal irradiation (CSI) on helical tomotherapy (HT).</article-title>
            <source>Technol Cancer Res Treat</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-36</page-range>
            <pub-id pub-id-type="pmid">24325133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gram</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haraldsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brodin</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Nysom</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rk-Eriksson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Munck Af Rosensch&#x000f6;ld</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Residual positioning errors and uncertainties for pediatric craniospinal irradiation and the impact of image guidance.</article-title>
            <source>Radiat Oncol</source>
            <year>2020</year>
            <month>Jun</month>
            <day>10</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>149</fpage>
            <pub-id pub-id-type="pmid">32522233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casanova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mazouni</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bieri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Combescure</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pica</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Whole brain radiotherapy with a conformational external beam radiation boost for lung cancer patients with 1-3 brain metastasis: a multi institutional study.</article-title>
            <source>Radiat Oncol</source>
            <year>2010</year>
            <month>Feb</month>
            <day>18</day>
            <volume>5</volume>
            <fpage>13</fpage>
            <pub-id pub-id-type="pmid">20167107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verellen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Ridder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Linthout</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tournel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Soete</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Storme</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Innovations in image-guided radiotherapy.</article-title>
            <source>Nat Rev Cancer</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>12</issue>
            <fpage>949</fpage>
            <page-range>949-60</page-range>
            <pub-id pub-id-type="pmid">18034185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMahon</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Larrier</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>QJ</given-names>
              </name>
            </person-group>
            <article-title>An image-guided technique for planning and verification of supine craniospinal irradiation.</article-title>
            <source>J Appl Clin Med Phys</source>
            <year>2011</year>
            <month>Jan</month>
            <day>31</day>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>3310</fpage>
            <pub-id pub-id-type="pmid">21587173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hansen</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Lukacova</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lassen-Ramshad</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Comparison of a new noncoplanar intensity-modulated radiation therapy technique for craniospinal irradiation with 3 coplanar techniques.</article-title>
            <source>Med Dosim</source>
            <year>2015</year>
            <season>Winter</season>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>296</fpage>
            <page-range>296-303</page-range>
            <pub-id pub-id-type="pmid">26002123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazzara</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Velthuizen</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Pearlman</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Brain tumor target volume determination for radiation treatment planning through automated MRI segmentation.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2004</year>
            <month>May</month>
            <day>01</day>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>300</fpage>
            <page-range>300-12</page-range>
            <pub-id pub-id-type="pmid">15093927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Wuu</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Jani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saraf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tai</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Lapa</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Andrew</surname>
                <given-names>JIS</given-names>
              </name>
              <name>
                <surname>Tiwari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saadatmand</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Isaacson</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TJC</given-names>
              </name>
            </person-group>
            <article-title>Whole-brain Irradiation Field Design: A Comparison of Parotid Dose.</article-title>
            <source>Med Dosim</source>
            <string-date>2017 Summer</string-date>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-149</page-range>
            <pub-id pub-id-type="pmid">28479012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis.</article-title>
            <source>BMC Cancer</source>
            <year>2019</year>
            <month>Nov</month>
            <day>14</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>1104</fpage>
            <pub-id pub-id-type="pmid">31727054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Harsh</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Lieberson</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Soltys</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2012</year>
            <month>Oct</month>
            <day>01</day>
            <volume>84</volume>
            <issue>2</issue>
            <fpage>336</fpage>
            <page-range>336-42</page-range>
            <pub-id pub-id-type="pmid">22652105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hardcastle</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tome</surname>
                <given-names>WA</given-names>
              </name>
            </person-group>
            <article-title>On a single isocenter volumetric modulated arc therapy SRS planning technique for multiple brain metastases.</article-title>
            <source>J Radiosurg SBRT</source>
            <year>2012</year>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">29296337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nahed</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Alvarez-Breckenridge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brastianos</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ammirati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ryken</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Kalkanis</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Surgery in the Management of Adults With Metastatic Brain Tumors.</article-title>
            <source>Neurosurgery</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>E152</fpage>
            <page-range>E152-E155</page-range>
            <pub-id pub-id-type="pmid">30629227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brennan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Hilden</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Lymberis</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Narayana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tabar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gutin</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Ballangrud</surname>
                <given-names>&#x000c5;</given-names>
              </name>
              <name>
                <surname>Lis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beal</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2014</year>
            <month>Jan</month>
            <day>01</day>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>130</fpage>
            <page-range>130-6</page-range>
            <pub-id pub-id-type="pmid">24331659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franchino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rud&#x000e0;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Soffietti</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms and Therapy for Cancer Metastasis to the Brain.</article-title>
            <source>Front Oncol</source>
            <year>2018</year>
            <volume>8</volume>
            <fpage>161</fpage>
            <pub-id pub-id-type="pmid">29881714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soliman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ruschin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Angelov</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>VLS</given-names>
              </name>
              <name>
                <surname>Kirkpatrick</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Sheehan</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Soltys</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Sahgal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Consensus Contouring Guidelines for Postoperative Completely Resected Cavity Stereotactic Radiosurgery for Brain Metastases.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2018</year>
            <month>Feb</month>
            <day>01</day>
            <volume>100</volume>
            <issue>2</issue>
            <fpage>436</fpage>
            <page-range>436-442</page-range>
            <pub-id pub-id-type="pmid">29157748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guti&#x000e9;rrez</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Westerly</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Tom&#x000e9;</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Jaradat</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Mackie</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Bentzen</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Khuntia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2007</year>
            <month>Oct</month>
            <day>01</day>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>589</fpage>
            <page-range>589-97</page-range>
            <pub-id pub-id-type="pmid">17869672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Dosimetric evaluation of four whole brain radiation therapy approaches with hippocampus and inner ear avoidance and simultaneous integrated boost for limited brain metastases.</article-title>
            <source>Radiat Oncol</source>
            <year>2019</year>
            <month>Mar</month>
            <day>15</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>46</fpage>
            <pub-id pub-id-type="pmid">30876444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patil</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Pricola</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sarmiento</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Sep</month>
            <day>25</day>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>CD006121</fpage>
            <pub-id pub-id-type="pmid">28945270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r113">
          <label>113</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Ahluwalia</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Asher</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Wefel</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Gondi</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>Feb</month>
            <day>10</day>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>483</fpage>
            <page-range>483-491</page-range>
            <pub-id pub-id-type="pmid">29272161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r114">
          <label>114</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ebi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nakajima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shishido</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Incidence of leukoencephalopathy after whole-brain radiation therapy for brain metastases.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2013</year>
            <month>Apr</month>
            <day>01</day>
            <volume>85</volume>
            <issue>5</issue>
            <fpage>1212</fpage>
            <page-range>1212-7</page-range>
            <pub-id pub-id-type="pmid">23102839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r115">
          <label>115</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conill</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berenguer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Soriano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valduvieco</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Marruecos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vilella</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Incidence of radiation-induced leukoencephalopathy after whole brain radiotherapy in patients with brain metastases.</article-title>
            <source>Clin Transl Oncol</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>590</fpage>
            <page-range>590-5</page-range>
            <pub-id pub-id-type="pmid">17921107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Safaee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McDermott</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Techniques for the Application of Stereotactic Head Frames Based on a 25-Year Experience.</article-title>
            <source>Cureus</source>
            <year>2016</year>
            <month>Mar</month>
            <day>25</day>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>e543</fpage>
            <pub-id pub-id-type="pmid">27158573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanguturi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Neurologic Complications of Radiation Therapy.</article-title>
            <source>Neurol Clin</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>599</fpage>
            <page-range>599-625</page-range>
            <pub-id pub-id-type="pmid">30072073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r118">
          <label>118</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiss</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Neurocognitive function after WBRT plus SRS or SRS alone.</article-title>
            <source>Lancet Oncol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>220</fpage>
            <page-range>220-1</page-range>
            <pub-id pub-id-type="pmid">20202605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r119">
          <label>119</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaspar</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rotman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Asbell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McKenna</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Byhardt</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>1997</year>
            <month>Mar</month>
            <day>01</day>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>745</fpage>
            <page-range>745-51</page-range>
            <pub-id pub-id-type="pmid">9128946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r120">
          <label>120</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaul</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Angelidis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Budach</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ghadjar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kufeld</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Badakhshi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer.</article-title>
            <source>Radiat Oncol</source>
            <year>2015</year>
            <month>Nov</month>
            <day>26</day>
            <volume>10</volume>
            <fpage>244</fpage>
            <pub-id pub-id-type="pmid">26611493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r121">
          <label>121</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>NU</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EQ</given-names>
              </name>
              <name>
                <surname>Aoyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barani</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Barboriak</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Baumert</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Bendszus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Camidge</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Dancey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Gaspar</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Hodi</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Kalkanis</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Linskey</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Margolin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Soffietti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>van den Bent</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Vogelbaum</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>PY</given-names>
              </name>
              <collab>Response Assessment in Neuro-Oncology (RANO) group</collab>
            </person-group>
            <article-title>Response assessment criteria for brain metastases: proposal from the RANO group.</article-title>
            <source>Lancet Oncol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>e270</fpage>
            <page-range>e270-8</page-range>
            <pub-id pub-id-type="pmid">26065612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r122">
          <label>122</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>van Zijl</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Fast 3D chemical exchange saturation transfer (CEST) imaging of the human brain.</article-title>
            <source>Magn Reson Med</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>638</fpage>
            <page-range>638-44</page-range>
            <pub-id pub-id-type="pmid">20632402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r123">
          <label>123</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehrabian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Detsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sahgal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stanisz</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Advanced Magnetic Resonance Imaging Techniques in Management of Brain Metastases.</article-title>
            <source>Front Oncol</source>
            <year>2019</year>
            <volume>9</volume>
            <fpage>440</fpage>
            <pub-id pub-id-type="pmid">31214496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32012.r124">
          <label>124</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pope</surname>
                <given-names>WB</given-names>
              </name>
            </person-group>
            <article-title>Brain metastases: neuroimaging.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2018</year>
            <volume>149</volume>
            <fpage>89</fpage>
            <page-range>89-112</page-range>
            <pub-id pub-id-type="pmid">29307364</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
